Evidation Health Completes Flare-Triggered Rheumatoid Arthritis Pilot With 29 Participants

Evidation Health has completed participant monitoring and biospecimen collection in its PACE pilot, a rheumatoid arthritis study that pairs symptom-triggered at-home blood draws with longitudinal health data. The company announced the milestone on November 12, 2026, according to Business Wire.

Inside the PACE Rheumatoid Arthritis Pilot

PACE, short for Precision in Autoimmune Condition Evidence, is described as the first study of its kind in rheumatoid arthritis to combine fully decentralized, symptom-triggered blood collection across baseline, flare and recovery states with longitudinal symptom reports, wearable measurements and clinical history. Evidation Health runs a direct-from-participant real-world data platform used by life sciences companies to capture longitudinal, multimodal health data.

Over approximately 60 days, 29 study participants contributed more than 1,300 daily symptom assessments that informed the timing of at-home blood collection. The study also included baseline genetic sampling. Designed as an initial pilot, PACE evaluated the feasibility of this sampling and data-linkage approach, with exploratory analyses planned to examine within-person changes in 251 inflammation-associated proteins across baseline, flare and recovery states.

PACE builds on Evidation's temporal proteomics platform, introduced in January 2026, with participants recruited from the company's autoimmune research cohort. Launched in November 2025, the cohort engages people living with autoimmune conditions through daily flare assessments, periodic surveys, and linked wearable and clinical data.

"Some of the most important changes in autoimmune disease happen between clinical visits, when researchers rarely capture biological data alongside detailed symptoms," said Leslie Oley Wilberforce, CEO of Evidation. "PACE is creating a first-of-its-kind view of the biological changes surrounding rheumatoid arthritis flares and recovery."

Evidation's Autoimmune Cohort Numbers

According to akta.pro company records, Evidation launched its Temporal Proteomics Platform in January 2026, an AI-enabled multiomics research platform integrating daily patient-reported outcomes, continuous wearable data, electronic health records and at-home biospecimen collection, seeded with a 3,500-participant autoimmune cohort. The same records show the company was founded in 2012, is headquartered in San Mateo, and has raised $259 million in total funding, with its last round a Series E of $153 million in March 2021.

As of October 2026, more than 4,400 individuals were participating in the autoimmune cohort across conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Sjögren's disease, inflammatory bowel disease and multiple sclerosis. More than 3,200 participants had completed at least 30 daily flare assessments, and more than 1,500 had reported at least one qualifying flare episode.

Where Evidation Presents Next

Evidation will share more about its autoimmune research platform during Fierce Biotech at London Life Sciences Week on November 17, 2026, in London, where Chief Medical Officer Sunny Khan, MPH, MBChB, MRCGP, will be speaking. The company said it will expand the approach across its growing autoimmune cohort.